scholarly journals Intradural Spinal Metastasis from Renal Cell Carcinoma: A Case Report

2001 ◽  
Vol 9 (2) ◽  
pp. 57-61 ◽  
Author(s):  
Kan-Hing Mak ◽  
John Ching-Kwong Kwok

Intradural spinal metastasis is rare. This is the third case ever reported on the finding of intradural spinal metastasis from a renal cell carcinoma that had been removed surgically. The patient had a history of epidural metastasis for which excision and anterior stabilization were done 3 years before the new presentation with cauda equina lesion. Seeding from the involved osseous structure to the cerebrospinal fluid through the dura was believed to be the course that tumour had taken to reach the intradural space.

Spine ◽  
2005 ◽  
Vol 30 (1) ◽  
pp. 161-163 ◽  
Author(s):  
Alex Alfieri ◽  
Guido Mazzoleni ◽  
Andreas Schwarz ◽  
Mauro Campello ◽  
Maximilian Broger ◽  
...  

Spine ◽  
2009 ◽  
Vol 34 (24) ◽  
pp. E892-E895 ◽  
Author(s):  
Dae-Yong Kim ◽  
Jung-Kil Lee ◽  
Sung-Jun Moon ◽  
Seok-Cheol Kim ◽  
Cheol-Su Kim

2011 ◽  
Vol 3 (2) ◽  
pp. 93-95 ◽  
Author(s):  
Bulent Citgez ◽  
Mehmet Uludag ◽  
Gurkan Yetkin ◽  
Esin Kabul Gurbulak ◽  
Banu Yılmaz Ozguven ◽  
...  

ABSTRACT Metastases to the thyroid gland are rare. We report the case of a 50-year-old man with an isolated thyroid metastasis from renal cell carcinoma (RCC), 3 years after radical nephrectomy for the primary disease. Although uncommon, if a patient with a previous history of malignancy has a new thyroid mass, it should be considered metastatic tumor of recurrent malignancy until proved otherwise.


2012 ◽  
Vol 2012 ◽  
pp. 1-3 ◽  
Author(s):  
Robert Deeb ◽  
Ziying Zhang ◽  
Tamer Ghanem

Renal cell carcinoma (RCC) is infamous for its unpredictable behavior and metastatic potential. We report a case of a patient with a complex history of multifocal renal cell carcinoma and chronic lymphocytic leukemia (CLL), who subsequently developed a parotid mass. Total parotidectomy revealed this mass to be an additional site of metastasis which had developed 19 years after his initial diagnosis of RCC.


1992 ◽  
Vol 59 (6) ◽  
pp. 54-56
Author(s):  
M. Giusto ◽  
F. Tuccia ◽  
D. Da Corte ◽  
C. Puccetti

Therapy for disseminated renal cell carcinoma is a major problem, as it's almost completely resistant to standard therapeutic approaches such as chemotherapy or radiotherapy. The search for innovative strategies has led to new concepts based on the assumption that cellular or soluble mediators of the immune system can be rendered cytotoxic or cytostatic for renal cell cancer. With partial response rates of ca. 100% and very promising global response rates, biotherapies are in progress. A number of clinical trials have been perfomed employing systemic administration of interferon (rIFN-) alone or in combination with cytostatic agents, human recombinant interleukin-2 (rlL-2), and, more recently, immunomodulatory agents such as lymphokine-activated killer (LAK) cells: these substances have been demonstrated to be a treatment of choice for advanced renal cell carcinoma, even if they seem unable to modify the natural history of the disease.


Rare Tumors ◽  
2016 ◽  
Vol 8 (4) ◽  
pp. 139-141 ◽  
Author(s):  
Mounir Errami ◽  
Vitali Margulis ◽  
Sergio Huerta

Because of the asymptomatic natural history of renal cell carcinoma (RCC), by the time a diagnosis is made, metastatic disease is present in about one third of the cases. Thus, the overall survival of patients with RCC remains poor. Ultimately up to 50% of patients with RCC will develop metastases. Metastatic lesions from RCC are usually observed in the lungs, liver or bone. Metastases to the brain or the skin from RCC are rare. Here we present a patient diagnosed with RCC, found to have no evidence of metastases at the time of nephrectomy, who presented two years later with metastases to the scalp. We review the literature of patients with this rare site of metastasis and outline the overall prognosis of this lesion compared to other site of metastases from RCC.


2020 ◽  
Vol 13 (10) ◽  
pp. e236051
Author(s):  
Nusrat Jahan ◽  
Shabnam Rehman

Metastatic tumours of the distal extremities, also known as acrometastases, are rare. The majority of the acrometastases involve bones—involvement of the soft tissues of the feet and hands is extremely rare. We report a case of clear cell renal cell carcinoma metastasised to the soft tissues of the foot. The patient presented with pain and swelling in his right foot. Diagnosis of acrometastases frequently gets delayed due to the rarity of this condition and resultant low clinical suspicion. Possibility of metastatic disease should be entertained as an important differential diagnosis when patients with a history of cancer present with musculoskeletal symptoms. A systematic evaluation incorporating thorough clinical assessment, advanced imaging techniques like MRI and pathological examination is critical to establish the diagnosis.


2019 ◽  
Vol 21 (Supplement_6) ◽  
pp. vi182-vi182 ◽  
Author(s):  
Na Tosha Gatson ◽  
Mayur Patel ◽  
Michelle Grant ◽  
Julie Woods ◽  
Gino Mongelluzzo ◽  
...  

Abstract With the success of immuno-oncotherapy (IO) to treat systemic cancers came the risk for multi-organ autoimmune inflammation (esophagitis, colitis, hypophysitis, pneumonitis, etc.). Immune-mediated encephalitis, however, has been only rarely described in patients treated on IO. Here we present the first case of a 70-year-old male with history of clear cell renal cell carcinoma (CCRCC, Fuhrman grade 4, April 2017) post-nephrectomy with early progressive pulmonary metastases treated with pazopanib before switching to single-agent nivolumab (February 2018) with demonstrated early response. Further progression (March 2019) added body irradiation and continued systemic nivolumab with questionable medication-induced dermatitis. Patient presented to ED in May 2019 with new-onset generalized tonic-clonic seizure, left visual field cut, and 4.6cm heterogeneous enhancing right occipital mass with vasogenic edema on brain MRI, presumed metastasis. However, unknown to the patient was a remote area of right occipital encephalomalacia (found on skull-based portion of staging PET, July 2018) presumed silent stroke or TBI endorsed 20-years-ago. Patient started anti-epileptic therapy and underwent negative CSF evaluation before neurosurgical resection. Tissue pathology concerning for lymphoproliferative malignancy versus reactive lymphocytic infiltrate with perivascular distribution of monomorphic CD4+ T-cell predominance (97%) and positive T-cell receptor (gamma, beta) gene rearrangement. While clonal T-cell populations are highly suggestive of T-cell malignancies, reactive conditions can also rarely show clonal T-cell populations. Patient underwent a negative systemic staging for lymphoma and IO was discontinued without immediate initiation of steroids. Follow up clinical evaluation reveal patient improved off IO therapy. Patient was determined to have reactive immune-mediated encephalitis secondary to IO therapy causing seizure mimicking brain metastasis of primary CCRCC. Interestingly, the prior area of encephalomalacia allowed for a cellular bed to collect, resembling brain mass. Upfront staging brain MRI prior to starting IO might have revealed susceptible area and could be considered in these patients


Sign in / Sign up

Export Citation Format

Share Document